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Background
The question, reported in the title of this editorial, has the pur-
pose of being intentionally a little provocative. It is obvious the
Ethical Committees (CE), founded and established to approve
clinical trials of new drugs that the pharmaceutical industry
intends to market and, in general, biomedical research such as
pharmaceutical no profit controlled clinical trials and observation-
al studies, are Bureaucratic Bodies. Indeed, they are a group of
people with various skills that work in compliance of well-defined
rules and laws in order to realize the common good of health on
the basis of criteria of impartiality, rationality, impersonality and,
mostly relevant, independence; property, this latter, that it is not
actually requested for a real Bureaucratic Body, but that is an
essential requisite for an Ethical Committee. So, the answer can
only be affirmative. 
It is however equally obvious that the above question refers
rather to the negative connotations of the term bureaucracy, such
as an inefficient, convoluted, too inflexible structure perched on
privileged positions to consider with extreme fussiness irrelevant
aspects and to formulate unnecessary requests for themselves to
meet absolutely non-substantial needs. Indeed, the current ques-
tion arises from an e-mail sent to me by a researcher working in a
hospital afferent to the CE Milan Area 3 (CEMiA-3).
The researcher’s complaints and outburst were due to the fact
that the CEMiA-3 did not immediately approved a study of which
she/he was the Principal Investigator. Indeed a suspension judge-
ment was expressed, requesting the clarification of several aspects
and the completion of some relevant documents, among which, in
the information sheet for the patients to be enrolled into the con-
trolled clinical trial, it had to be reported the time and the place of
conservation of the biological samples (now suspended by you
because there is no written as long as we keep the samples and
where: at the XY or XZ hospital! and it goes next year! Was not a
phone call enough?, just for reporting the exact text).
Furthermore, she/he wrote This CE would not be able to approve
the discovery of the wheel or the fire for a thousand pretexts on the
experimental plane or on the danger ... in short, it lacks courage
and confidence in the talented Researcher and gets entrenched in
the bureaucracy.
Obviously, the talented researcher with capital R, as she/he
wrote, had only grasped the aspect of the conservation of the biop-
sy specimens which is, let me to say, a minor flaw compared to the
shortcomings and mistakes that the CEs systematically find in the
documentation of the studies submitted for their judgement.
However, it must be recognized that what the researcher wrote
is a widely held opinion of the physicians/researchers who have to
interact with the CEs and the aim of this Editorial is precisely that
of trying to start to build a bridge of understanding and collabora-
tion; indeed, it is clear that if the ECs and the researchers remain
seated on the opposite banks of a river, they may perhaps recog-
nize who it belongs the body that passes first in the river stream,
but certainly they will never actively communicate.
I have to say that first of all I asked myself how it is possible
to make clinical researcher understand that the EC do not make
mere vexatious requests of a bureaucratic nature. I argued that,
since the physicians member of the CEs, do not share this opinion
but rather take it for granted that they are absolutely legitimate, a
solution could be to impose a period of mandatory participation in
the work of the ethics committees to all the clinicians and
researchers. However, I must say, this solution could be impracti-
cal and even counterproductive.
In addition, I also wondered if it is ever possible to establish
an active relationship of mutual collaboration between the CEs
and the clinical researchers, given that every time the CE tried to
do it through several workshops that I have proposed and con-
tributed to organize for this purpose, the participation of
researchers was extremely scarce and practically null. 
I refer to the following three workshops held at the ASST
Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Workshop Il Comitato Etico di Niguarda e La
Sperimentazione Clinica. 27th September 2006. [Niguarda’s
Ethics Committee and Clinical Trial]. 
Workshop del Comitato Etico dell’Azienda Ospedaliera
Ospedale Niguarda Ca’ Granda: Sperimentazioni Cliniche:
Nuovo Decreto Ministeriale Clinical Trial Application (CTA).
29th September 2008. [Workshop of the Ethics Committee of the
Hospital Agency Hospital Niguarda Ca’ Granda: New Ministerial
Decree Clinical Trial Application (CTA).
Workshop del Comitato Etico dell’Azienda Ospedaliera
Ospedale Niguarda Ca’ Granda: Validità del consenso informato
ed applicabilità nelle situazioni critiche. Lo stato dell’arte degli
aspetti normativi e le sfide per il futuro. 27th September 2012.
[Workshop of the Ethical Committee of the Hospital Agency
Hospital Niguarda Ca’ Granda: Validity of informed consent and
applicability in critical situations. The state of the art of regulatory
aspects and challenges for the future.] 
Finally, I refer to the recent conference: Quale prospettive per
i Comitati Etici in Italia?, 1 December 2017, Bergamo, Italy.
[Conference: What prospects for the Ethics Committees in Italy?]
The requests of the ECs are bureaucratic acts?
First of all, it has to be considered that the ECs are not
sovereign and have to answer for their work to the Agenzia
Italiana del Farmaco (AIFA, established by the Law 326 of 2003)1
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to which the Law n.189 of 8 November 2012 recognizes the role
of competent authority for the evaluation of clinical trials with
drugs.2 Therefore, it seems that the EC has to play the role of being
a kind of interface between researchers and AIFA trying to prevent
that AIFA does not approve their trials with drugs.
In addition, as also the so-called Balduzzi Decree points out,3
the ECs must take their actions and issue their judgements by
inspiring to non-normative reference documents such as: i) The
Helsinki Declaration, 2013;4 ii) The Oviedo Convention,5 which
was ratified in Italy by the law of 28 March 2001,6 but this ratifi-
cation has not yet been filed making it practically ineffective in
Italy; indeed, it has to do a subsequent deposit of the instrument of
ratification in the Council of Europe for making this ratification
effective;7 iii) the rules of “good clinical practice (GCP);8,9 iv) the
updated guidelines of the European Agency (EMA) such as the
ICH E8,10 the ICH E9,11 with its revision ICH E9(R1);12 v) but
also, and above all, the laws of the Italian State such as the
Legislative Decree of 24 June 2003 n 211.13
The requests, such as those that have triggered the protests of
the researcher, are carried out on specific current indications of the
Guarantee of Privacy such as i) the authorization No. 9/2016,14 that
considers the conservation of data and samples together with their
security referring also to ii) the provision of 24 July 2008,15 which
also takes into account the problems of the data transfer abroad and
the relevant ways to inform patients; iii) the Authorization 8/2016
concerning genetic data also in the field of research,16 with the
problem related to the request of a further consent ranging from the
broad consent to the blanket consent for future genetic investiga-
tions also considered, together with the topic of the biobanks in the
biomedical research, by relevant guidelines of the National
Bioethics Committee.17 About this point, it cannot be left out the
famous guideline written in 2006 by the Smith Kline foundation
and the Italian Society of Human Genetics,18 even if it is aimed pri-
marily at genetic studies that are completely different from the so-
called “substudies” on genotypes of patients primarily aimed at
identifying potential prognostic factors, usually proposed as a
corollary in controlled clinical trials, particularly in oncology.
Then, also the request to include in the information sheet at
least the details of the insurance policy is a minimum requirement
compared to the requirements of the Decree July 14, 2009 on
insurance (the investigator is always required to inform the partic-
ipants to the trial protocol, even through the informed consent…
Article 1, Point 6).19 It has to point out that, according to the
Decree, the ECs judgement is null by law in the absence of an
appropriate insurance policy. It has also to be reported that the ECs
are so blind bureaucrats that they almost usually accept the formal
commitment of the sponsors to take out an appropriate insurance
once the favourable judgement has been obtained, since it seems
acceptable and sensible that the sponsors face additional economic
charges only if they are appropriate.
In conclusion, these requests are to be considered absolutely in
line with the principles of GCP and their revision to which the ECs
inspire their work,8,9 principles that can be extended to other types
of studies in addition to the controlled clinical trials on medicinal
products. 
Thus, ECs demands must be considered not as the expression
of a boring and dull bureaucracy, but rather as the expression of
attention, consideration and respect towards a patient who is
required to express informed consent consciously and freely.
Indeed, it has to point out that the first mission of the ECs is the
guarantee and protection of the patient, who constitutes the weak-
est and most suggestible link in the chain: patient, medical
Researcher, AIFA, ethical committee, Pharmaceutical Industry,
CRO, etc.
As a further comment, it is curious that the researchers do not
complain so wildly about the strict rules, such as the fixed number
of words, when they fill the application forms for obtaining funds
for their research from some Agencies such as Telethon, Cariplo,
Regione Lombardia, AIFA, International Agency For Research on
Cancer (IARC), Horizon 2020, European Funds, Progetti di
Ricerca di Interesse Nazionale (PRIN), etc.
The adherence to the laws of the country canbe considered a bureaucratic act?
In addition to bureaucrats only able to put the sticks in the
wheels, the ECs are also considered cowards when they do not
authorize the so-called deferred consent in the case of an adult
unable to express her/his informed consent and without a legal rep-
resentative. In particular the EC, established by the Decree of 15
July 1997, Article 4,20 were regulated by the Decree of March 8,
1998 which,21 at point 3.7.8 considered the so-called deferred con-
sent to be acceptable following the ICH E6 GCP.8 Indeed, the ICH
E6 guideline defines the informed consent at the point 1.28,8
devoting to this topic a large space compared to the randomization,
for example, which is considered only in a short five lines para-
graph, and, finally, consider the deferred consent at the point
4.8.15. However, in the subsequent Decree 211 of 24 June 2003,22
the deferred consent is no longer considered acceptable as can be
seen in Article 3 where only the legal representative of the person
who is not able to providing informed consent is entitled to provide
it in its place and also with particular limitations considered in the
following Article 5.
How much and where the problems, misunderstandings and conflicts between theECs and the researchers are more relevant?
I have to point out that the requests of the ECs are particularly
relevant and numerous in the context of the research on medicinal
products so-called no profit (characteristics that the CEs must care-
fully verify) that, according to the 15th AIFA Report on Clinical
Trials in Italy,23 constitutes just a little less than a third of all the
studies. In addition, this kind of research is particularly supported
by the legislator with the Decree 17 December 200424 and also
with the recent Law Lorenzin.25
Indeed, the research no profit or independent presents the
greatest criticality as researchers have to face a series of obliga-
tions that require specific skills, adequate equipment and the nec-
essary funds: perhaps, the funds given by the pharmaceutical
industry, as occurs in various circumstances, should be intended
for the involvement of an Organizzazione di Ricerca a Contratto
(CRO)26 to support all the aspects of the planning and conducting
a research. 
I am convinced and I want to support the thesis that in reality
the researchers R capital with or without talent do not necessarily
have to be aware of all the specific and detailed aspects that are
associated with the drafting of documents to be set up for the
request of the CEs judgement. In fact the researchers have to be
fully supported in the path that runs from the conception of an idea
(more or less spontaneously matured) to the presentation of the
appropriate documentation to the ECs.
To this regard, I want to remember the Fondazione per la
Ricerca Ospedale Maggiore di Bergamo (FROM) a non-university
foundation at the ASST Papa Giovanni XXIII, and the recently
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founded Dipartimento di formazione e ricerca at the ASST Grande
Ospedale Metropolitano Niguarda having precisely the aforemen-
tioned tasks and purposes.
In addition, I like to particularly mention the AIFA project of a
few years ago, called the quality in non-profit clinical experimen-
tation,27 in which the characteristics necessary for the establish-
ment of a Clinical Trial Quality Team (CTQT) were identified,
defining its composition, operational details and skills, and also the
timing of activation and implementation of its activities.
I firmly believe that these structures of which there is a list dat-
ing back to 2010 of a dozen centres, especially placed in Istituti di
Ricovero e Cura a Carattere Scientifico (IRCCS) and Universities
with characteristics similar to the Clinical Trials Unit set up
abroad, almost exclusively at University level and gathered in a
specific network (website: http://www.ukcrc-ctu.org.uk/), consti-
tute the only way to overcome problems of misunderstandings and
conflicts, to relieve the EC from an activity of mere control that
diminishes its mission and its work and to win the challenge of
independent and effectively no profit research that researchers can-
not face alone as a trans-oceanic solitaire.
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